Abstract 939P
Background
Patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who failed platinum and/or immune check-point inhibitor have a poor prognosis with OS~6 moths. Epidermal growth factor receptor (EGFR) is aberrantly over-expressed in R/M SCCHN pts with high frequency. MRG003 is a novel ADC composed of a humanized anti-EGFR mAb conjugated to MMAE via a vc-linker. This study was designed to evaluate the efficacy and safety of MRG003 in R/M SCCHN.
Methods
Histologically or cytologically confirmed R/M SCCHN (including oral cavity, oropharynx, hypopharynx, and larynx) pts were divided into two groups of MRG003 (2.0 or 2.3 mg/kg, Q3W). Eligible pts were aged 18-75 years old and had progressed at least one line of standard therapy. The primary endpoint was the objective response rate (ORR). The secondary endpoints included disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and safety.
Results
Sixty-seven pts in total were enrolled with 35 pts received 2.0 mg/kg of MRG003, and 32 pts received 2.3 mg/kg. The median age was 54 (26-75) years, and 91% of pts’ ECOG performance status was 1. The immunohistochemistry detection of EGFR expression was performed in 65 pts, and 62 pts (95.4%) were EGFR-positive. The median line of prior therapy was 2 (1-5). Most pts had received prior platinum (95.6%), PD-1/L1 inhibitor (76.1%), cetuximab (47.8%). At the data cutoff, the ORR was 30.6% in all EGFR-positive pts. In the 2.3 mg/kg dose group, the ORR and DCR was 43% and 86% in 2/3-line pts who had failed prior platinum and PD-1/L1 inhibitor, and the mPFS and mOS were 4.2 months and 11.3 months, respectively. The common treatment-related adverse events (TRAEs) included constipation (25.8%), pruritus (24.2%), and anemia (22.6%). Common grade 3 or above TRAEs included white blood cell count decreased (6.5%), anemia (4.8%).
Conclusions
MRG003 was well tolerated with a manageable safety profile, and showed promising efficacy in 2/3-line R/M SCCHN pts who failed prior platinum and PD-1/L1inhibitor. A phase III study is currently ongoing to further explore the efficacy of MRG003 in compared with cetuximab/methotrexate in this setting.
Clinical trial identification
NCT04868162 First Posted: April 30, 2021.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Miracogen Inc.
Funding
Shanghai Miracogen Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
919P - A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients
Presenter: Wu xi
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12